Related Experiment Video
Updated: Jun 18, 2026

A Reproducible Intensive Care Unit-Oriented Endotoxin Model in Rats
Published on: February 20, 2021
Indolicidin Attenuates Inflammation by Modulating the TLR4 Signaling Pathway during Sepsis Progression
Zhishang Shi1, Yanting Wang1, Yijun Gu1
1National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, College of Life Sciences, Nankai University, Tianjin 300071, China.
Abstract:
Sepsis is characterized by dysregulated inflammatory responses triggered by pathogen-associated molecular patterns (PAMPs) and remains a major cause of mortality worldwide. Although antibiotics are widely used for the treatment of sepsis-associated infections, their clinical efficacy is often limited by antimicrobial resistance and the inability to control excessive inflammatory responses. Indolicidin is a bovine-derived antimicrobial peptide with antimicrobial and immunomodulatory activities; however, its anti-inflammatory mechanisms in sepsis remain unclear. In this study, we investigated the protective effects and mechanisms of indolicidin in bacterial and fungal sepsis models. The results showed that indolicidin exhibited good biocompatibility both in vitro and in vivo. In murine models of Escherichia coli- and Candida albicans-induced sepsis, indolicidin significantly improved survival and reduced microbial burden in the kidneys. In RAW264.7 macrophages stimulated with lipopolysaccharide (LPS), a major PAMP of E. coli, indolicidin suppressed M1 polarization, reactive oxygen species production, and proinflammatory cytokine expression. Transcriptomic analyses of macrophages and infected kidney tissues revealed that indolicidin consistently downregulated inflammation-related pathways, chemokine signaling, and LPS-response pathways, including genes associated with IL-6, chemokines, and M1 macrophage markers such as CD80 and CD86. Mechanistically, indolicidin directly bound LPS, interacted with lipopolysaccharide-binding protein (LBP), and reduced the surface expression of CD14 and the TLR4/MD2 complex, indicating modulation of the TLR4 signaling pathway. Overall, this study highlights indolicidin as a dual-function peptide with antimicrobial and immunomodulatory activity and supports its potential as a therapeutic candidate against sepsis.
Insights
Indolicidin, a bovine peptide, shows promise for sepsis treatment by fighting infections and reducing harmful inflammation. It effectively improves survival rates and modulates immune responses in sepsis models.
Area of Science:
- Immunology
- Microbiology
- Pharmacology
Background:
- Sepsis is a life-threatening condition with high mortality, often inadequately treated by antibiotics due to resistance and uncontrolled inflammation.
- Antimicrobial peptides (AMPs) like indolicidin possess both antimicrobial and immunomodulatory properties, but their specific anti-inflammatory roles in sepsis require elucidation.
Purpose of the Study:
- To investigate the protective effects and underlying mechanisms of indolicidin in bacterial and fungal sepsis models.
- To assess indolicidin's biocompatibility and its impact on inflammatory pathways and microbial burden.
Main Methods:
- Sepsis models were established using *Escherichia coli* and *Candida albicans* in mice.
- RAW264.7 macrophages were stimulated with lipopolysaccharide (LPS) to evaluate indolicidin's effects on M1 polarization, reactive oxygen species (ROS), and cytokine production.
- Transcriptomic analysis was performed on macrophages and kidney tissues.
- Mechanistic studies involved assessing indolicidin's interaction with LPS, lipopolysaccharide-binding protein (LBP), and the Toll-like receptor 4 (TLR4) signaling complex.
Main Results:
- Indolicidin demonstrated good biocompatibility in vitro and in vivo.
- It significantly improved survival rates and reduced kidney microbial load in murine sepsis models.
- Indolicidin suppressed M1 macrophage polarization, ROS production, and pro-inflammatory cytokine expression.
- Transcriptomic data revealed downregulation of inflammation, chemokine signaling, and LPS-response pathways, including key genes like IL-6, CD80, and CD86.
- Mechanistically, indolicidin bound LPS, interfered with LBP, and reduced CD14 and TLR4/MD2 complex expression, indicating TLR4 pathway modulation.
Conclusions:
- Indolicidin exhibits dual antimicrobial and immunomodulatory functions beneficial in sepsis.
- It protects against bacterial and fungal sepsis by reducing microbial burden and suppressing excessive inflammation via TLR4 pathway modulation.
- Indolicidin represents a potential therapeutic candidate for sepsis treatment.
Related Concept Videos
Acute Inflammation III: Local and Systemic Effects
Gene Regulation in Microbial Communities: Quorum Sensing
Inflammatory Bowel Disease III: Crohn's Disease
Inflammatory Response
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Inflammatory Bowel Disease II: Ulcerative Colitis
Regulation of Bacterial Virulence
